Brian Elsbernd
Chief Legal and Compliance Officer at Catalyst Pharmaceuticals - Coral Gables, FL, US
Brian Elsbernd's Colleagues at Catalyst Pharmaceuticals
Scott Szedlock
Fort Lauderdale Area - Associate Director of Formulation and Product Development
Brian Elsbernd's Contact Details
305-420-3200
Catalyst Pharmaceuticals
Brian Elsbernd's Company Details
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.